Printer Friendly

ZYNAXIS, INC. COMPLETES PUBLIC OFFERING OF 2.5 MILLION SHARES

 ZYNAXIS, INC. COMPLETES PUBLIC OFFERING OF 2.5 MILLION SHARES
 MALVERN, Pa., Jan. 30 /PRNewswire/ -- Zynaxis, Inc. (NASDAQ-NMS: ZYNX) announced today the initial public offering of 2.5 million shares of common stock at a price of $9 per share.
 All of the shares will be sold by the company.
 The offering is being managed by Pennsylvania Merchant Group Ltd. and Hanifen, Imhoff Inc.
 The net proceeds from the offering will be used for product research and development activities, reduction of debt and general corporate purposes.
 Zynaxis, Inc. commenced business in 1988 to discover, develop and commercialize new therapeutic delivery systems and diagnostic products. The company's current research efforts are focused on the development of products for delivery of antiproliferative drugs for the reduction of restenosis following angioplasty, the palliation of pain and the treatment of chronic inflammation resulting from rheumatoid arthritis, the treatment of ovarian cancer and the treatment of psoriasis. Zynaxis, Inc. is also developing cellular diagnostic products for the measurement and monitoring of certain cell types.
 /delval/
 -0- 1/30/92
 /CONTACT: Thomas Cekoric Jr., president and chief executive officer of Zynaxis, 215-889-2200/ CO: Zynaxis, Inc. ST: Pennsylvania IN: MTC SU: OFR


JS-KA -- PH013 -- 5191 01/30/92 11:12 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 30, 1992
Words:204
Previous Article:WETTERAU CALLS FOR REDEMPTION ITS 7-3/4 PERCENT SENIOR NOTES TO BE REDEEMED ON FEB. 28, 1992
Next Article:CENTEX REPORTS THIRD QUARTER AND NINE MONTHS RESULTS
Topics:


Related Articles
ZYNAXIS, INC. FILES FOR PROPOSED PUBLIC OFFERING
OVER-ALLOTMENT OPTION EXERCISED IN ZYNAXIS PUBLIC OFFERING
ZYNAXIS REPORTS FIRST QUARTER RESULTS
ZYNAXIS REPORTS SECOND QUARTER AND SIX MONTH RESULTS
WALTER BRANDES JOINS ZYNAXIS AS VICE PRESIDENT OF SALES AND MARKETING
MICHAEL CHRISTIE, PH.D. JOINS ZYNAXIS AS VICE PRESIDENT OF PROCESS DEVELOPMENT
ZYNAXIS REPORTS THIRD QUARTER AND NINE MONTH RESULTS
ZYNAXIS REPORTS FOURTH QUARTER AND YEAR END RESULTS
ZYNAXIS AND SECRETECH ANNOUNCE MERGER PLANS; FOCUS ON DRUG DELIVERY STRENGTHENED
Genelabs Technologies Raises $9 Million in Private Placement Financing.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters